Recombinant Human Atrial natriuretic peptide receptor 3 (NPR3)

What is the molecular structure of recombinant human NPR3?

Recombinant Human NPR3 is a type I transmembrane glycoprotein consisting of a 455 amino acid extracellular domain (ECD), a 23 amino acid transmembrane segment, and a 37 amino acid cytoplasmic region. The protein exhibits high evolutionary conservation, with the human NPR3 ECD sharing 92% amino acid sequence identity with mouse and rat NPR3 . When analyzed by SDS-PAGE, the Recombinant Human NPR3 Fc Chimera resolves at 78-92 kDa under reducing conditions and 160-200 kDa under non-reducing conditions, indicating proper disulfide bond formation .

What are the primary biological functions of NPR3?

NPR3 serves several critical physiological functions:

• Clearance receptor - Removes natriuretic peptides (ANP, BNP, and CNP) from circulation, thereby regulating their bioavailability

• Signaling modulator - Participates in natriuretic peptide system regulation, which maintains cardiovascular homeostasis

• Tissue-specific roles - Contributes to renal physiology, particularly in podocytes, where it is highly expressed

• Developmental influence - Interacts with Osteocrin to regulate bone elongation, specifically affecting femoral, tibial, and metatarsal development

Where is NPR3 predominantly expressed in human tissues?

NPR3 demonstrates a broad tissue distribution pattern, with notable expression in:

This extensive expression profile suggests diverse physiological roles beyond simple peptide clearance .

What are the optimal methods for reconstituting and storing recombinant human NPR3?

Recombinant Human NPR3 Fc Chimera protein is typically supplied as a lyophilized powder from a 0.2 μm filtered solution in PBS with Trehalose. For optimal experimental outcomes, follow these methodological guidelines:

• Reconstitution:

  • Reconstitute at a concentration of 500 μg/mL in PBS

  • Allow complete dissolution with gentle mixing

  • Avoid vigorous agitation that may compromise protein structure

• Storage recommendations:

  • Store the lyophilized product at appropriate temperature (typically -20°C to -80°C)

  • After reconstitution, create small aliquots to prevent repeated freeze-thaw cycles

  • Use a manual defrost freezer and maintain consistent storage conditions

• Formulation considerations:

  • Standard preparations contain Bovine Serum Albumin (BSA) as a carrier protein

  • For applications where BSA might interfere, carrier-free versions are available

  • Consider the specific requirements of your experimental system when selecting formulations

How can researchers validate the functionality of recombinant NPR3?

Functional validation of recombinant NPR3 requires multiple complementary approaches:

• Binding assays:

  • When immobilized at 2 μg/mL, Recombinant Human NPR3 Fc Chimera binds to Recombinant Human Osteocrin with an ED₅₀ of 2-20 ng/mL

  • Similar binding studies can be performed with natriuretic peptides (ANP, BNP, CNP)

  • Competition assays can determine relative binding affinities

• Structural integrity assessment:

  • SDS-PAGE analysis under reducing and non-reducing conditions

  • Visual confirmation by Coomassie Blue staining

  • Western blot using specific antibodies

• Functional consequences measurement:

  • Effect on natriuretic peptide clearance rates

  • Impact on downstream signaling pathways

  • Cellular localization studies using tagged constructs

How do genetic variants of NPR3 affect protein function and stability?

Comprehensive resequencing studies have identified 105 polymorphisms in NPR3, 50 of which were novel, including 8 nonsynonymous single-nucleotide polymorphisms (SNPs) . Functional genomic analyses of these variants have revealed significant impacts on protein expression and stability:

• The Arg146 variant allozyme demonstrates dramatically reduced expression (20% of wild-type protein levels), primarily due to autophagy-dependent degradation mechanisms

• Structural modeling confirms that variants like Arg146 can result in:

  • Protein misfolding

  • Reduced structural stability

  • Altered ligand binding properties

• Methodological approach for variant characterization:

  • Expression constructs for wild-type and variant allozymes transfected into HEK293 cells

  • Quantitative Western blot analysis to measure recombinant protein expression

  • Structural modeling to predict conformational changes

  • Degradation pathway analysis through autophagy inhibition

These genetic variations could significantly affect natriuretic peptide clearance rates, potentially altering cardiovascular homeostasis and disease susceptibility.

What role does NPR3 play in renal physiology and kidney disease?

NPR3 demonstrates significant expression in kidney tissue, particularly in podocytes, suggesting an important role in renal function. Experimental investigation using both genetic and pharmacological approaches has yielded valuable insights:

These findings suggest that NPR3 may contribute to kidney disease progression, potentially through mechanisms involving natriuretic peptide signaling regulation.

What experimental controls are essential when conducting NPR3 binding studies?

Rigorous binding studies with recombinant NPR3 require careful consideration of multiple controls to ensure data reliability:

• Positive controls:

  • Known ligands (ANP, BNP, CNP, Osteocrin) at established concentrations

  • Validated recombinant NPR3 preparations with documented binding activity

• Negative controls:

  • Non-binding proteins of similar size and charge characteristics

  • Buffer-only conditions to establish baseline signals

• Specificity controls:

  • Competition assays with unlabeled ligands

  • Blocking studies using anti-NPR3 antibodies

  • Structurally related but non-binding peptides

• Technical validation:

  • Multiple independent experimental replicates

  • Different detection methods when possible

  • Concentration-response curves to establish ED₅₀ values

  • Internal standards for normalization between experiments

How can researchers troubleshoot expression problems with recombinant NPR3 variants?

Expression challenges are common when working with NPR3 variants, particularly those affecting protein folding or stability. Methodological approaches to address these issues include:

• For the Arg146 variant with 80% reduced expression:

  • Include autophagy inhibitors during expression to prevent degradation

  • Optimize culture conditions (temperature, media composition)

  • Consider co-expression with molecular chaperones

• General expression optimization strategies:

  • Test multiple expression systems (bacterial, mammalian, insect cells)

  • Evaluate different promoter strengths and induction conditions

  • Create fusion constructs with stabilizing partners

  • Engineer constructs with specific domain deletions or modifications

• Analytical approaches to identify problems:

  • Pulse-chase experiments to determine protein half-life

  • Subcellular fractionation to locate protein accumulation

  • Proteasome and lysosome inhibitor studies to identify degradation pathways

How does NPR3 contribute to cardiovascular homeostasis and disease?

NPR3's role in cardiovascular function stems from its position as a key regulator in the natriuretic peptide system:

• Physiological mechanism:

  • Acts as the primary clearance receptor for natriuretic peptides

  • Regulates the bioavailability of ANP and BNP, which have vasodilatory and natriuretic effects

  • Contributes to blood pressure regulation and cardiovascular homeostasis

• Disease associations:

  • Genetic variation in NPR3 has been linked to hypertension

  • May influence heart failure pathophysiology through natriuretic peptide clearance rates

  • Potential contribution to cardiovascular risk factors like obesity

• Experimental evidence from model systems:

  • NPR3 genetic variants affect protein expression and stability

  • Altered NPR3 function may disrupt normal natriuretic peptide signaling

  • Pharmacological modulation of NPR3 affects cardiovascular parameters

What are the methodological approaches for studying NPR3 in complex disease models?

Investigating NPR3 in disease contexts requires sophisticated experimental designs:

• Integrated genetic and pharmacological strategies:

  • Generation of tissue-specific knockout models (e.g., podKO NPR3)

  • Selective NPR3 inhibitors (NPR3i) for pharmacological intervention

  • Combined approaches to distinguish developmental from acute effects

• Disease model selection:

  • Nephrotoxic serum (NTS) model for acute kidney injury

  • ZSF1 rat model for diabetic kidney disease

  • Combined with genetic manipulation or pharmacological intervention

• Multi-parameter outcome assessment:

  • Histological analysis (e.g., glomerulosclerosis quantification)

  • Functional measurements (e.g., albuminuria)

  • Cellular markers (e.g., podocyte loss)

  • Molecular signaling evaluation

• Combination therapy evaluation:

  • Testing NPR3i alongside established treatments (e.g., losartan)

  • Potential synergistic effects of targeting multiple pathways

  • Dose-response relationships in combination settings